Mostrar el registro sencillo del ítem

Ionic gradient liposomes: Recent advances in the stable entrapment and prolonged released of local anesthetics and anticancer drugs

dc.contributor.authorFatima M.T.
dc.contributor.authorIslam Z.
dc.contributor.authorAhmad E.
dc.contributor.authorBarreto G.E.
dc.contributor.authorMd Ashraf G.
dc.date.accessioned2020-09-02T22:17:24Z
dc.date.available2020-09-02T22:17:24Z
dc.date.issued2018
dc.identifier10.1016/j.biopha.2018.07.138
dc.identifier.citation107, , 34-43
dc.identifier.issn07533322
dc.identifier.urihttps://hdl.handle.net/20.500.12728/4425
dc.descriptionLiposomes have established themselves as great pharmaceutical carriers over the past three decades. These phospholipid vesicular systems have undergone great technical advances including remote drug loading, targeted delivery, and combinatorial drug therapy. Ionic gradient liposomes (IGL) necessitates active loading of the drug in preformed vesicles exhibiting a transmembrane pH or ion gradient, with a low intra liposome pH (∼ 4-5), and a high outside pH (∼7-8). It allows high drug encapsulation and prolonged release, particularly for amphipathic weak acids and weak bases. Most local anesthetics (Bupivacaine, Ropivacaine, Tetracaine, and others) have a pka in the range of 7-9, which makes them ideal candidates for their entrapment in IGL. The same is true for most anthracyclines which have great anti-tumor properties (Doxorubicin, Daunorubicin, Idarubicin, and others). Many FDA approved liposomal drugs utilise ion gradient for their encapsulation. Considering their immense utility, we summarize here in this review, the recent contributions made by various research groups utilizing IGL, to accentuate the development of these carriers in drug delivery. This would possibly be helpful in carrying new investigations and further contributions in the optimization and advancements of new drugs for better therapeutics. © 2018 Elsevier Masson SAS
dc.language.isoen
dc.publisherElsevier Masson SAS
dc.subjectAnthracyclines
dc.subjectControlled release
dc.subjectDrug delivery
dc.subjectEntrapment
dc.subjectIonic gradient liposomes
dc.subjectLocal anesthetics
dc.subjectpKa
dc.subjectWeak base
dc.subjectanthracycline
dc.subjectantineoplastic agent
dc.subjectionic gradient liposome
dc.subjectliposome
dc.subjectlocal anesthetic agent
dc.subjectunclassified drug
dc.subjectantineoplastic agent
dc.subjection
dc.subjectliposome
dc.subjectlocal anesthetic agent
dc.subjectconcentration ratio
dc.subjectdrug concentration
dc.subjectdrug delivery system
dc.subjectdrug release
dc.subjectdrug retention
dc.subjectencapsulation
dc.subjecthuman
dc.subjectlipophilicity
dc.subjectmicelle
dc.subjectnonhuman
dc.subjectpH
dc.subjectphysical chemistry
dc.subjectpriority journal
dc.subjectReview
dc.subjecttemperature sensitivity
dc.subjectdelayed release formulation
dc.subjectpharmacology
dc.subjectAnesthetics, Local
dc.subjectAntineoplastic Agents
dc.subjectDelayed-Action Preparations
dc.subjectIons
dc.subjectLiposomes
dc.titleIonic gradient liposomes: Recent advances in the stable entrapment and prolonged released of local anesthetics and anticancer drugs
dc.typeReview


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-85050810514.pdf
Tamaño:
3.352Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem